Anthrogen CEO Kim Mi-hyung: "Beyond pain relief, we saw potential for cartilage regeneration with an injection"
Predicted impact: Low
CEO interview on cartilage regeneration potential; vague, no financial size or regulatory milestone disclosed.
065660 · KOSDAQ · ₩065660 · 안트로젠
Predicted impact: Low
CEO interview on cartilage regeneration potential; vague, no financial size or regulatory milestone disclosed.
Also known as: Anterogen / 안트로젠 / 065660 / KRX:065660
Source: KRX statistical information